Ironwood screens as a statistically cheap, high-quality growth business with elite margins and positive technical momentum, but the engine's own risk/reward gate and bearish insider/short-interest signals argue for a smaller starter position until the asymmetry improves.
Thesis pillars
- High Quality Margin Profile→Stable
- Deep Value Mispricing→Stable
- Technical Momentum Above 200dma↑Improving
- +2 more pillars — see the Why tab for full reasoning
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Analysis
Temporary headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $3.58. Weak momentum — blocks BUY_NOW at $3.76. Engine's entry $3.58 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Falling knife score: 6.5/10.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the... Read more
Wait for pullback to $3.58. Weak momentum — blocks BUY_NOW at $3.76. Engine's entry $3.58 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Falling knife score: 6.5/10. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 80% MoS with quality 8.9. | Falling knife (FK=6.5): wait for stabilization. Score 7.4/10, high confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-10-13Recent Developments — Ironwood Pharmaceuticals, Inc.
Latest news
- NEWS IRWD|Ironwood Pharmaceuticals Inc|Price:3.805|Chg%:-0.105 - TradingKey — TradingKey neutral
- NEWS IRWD|Ironwood Pharmaceuticals Inc|Price:3.805|Chg%:-0.105 - tradingkey.com — tradingkey.com neutral
- NEWS Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com — tradingkey.com neutral
- NEWS Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha — Seeking Alpha negative
Generated 2026-10-13T11:27:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·3 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $3.58. Weak momentum — blocks BUY_NOW at $3.76. Engine's entry $3.58 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Falling knife score: 6.5/10. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 80% MoS with quality 8.9. | Falling knife (FK=6.5): wait for stabilization. Target $5.18 (+37.8%), stop $3.43 (−9.6%), A.R:R 3.8:1. Score 7.4/10, high confidence.
Take-profit target: $5.18 (+37.9% upside). Target $5.18 (+37.8%), stop $3.43 (−9.6%), A.R:R 3.8:1. Stop-loss: $3.43.
Negative momentum; Falling knife score: 6.5/10.
Ironwood Pharmaceuticals, Inc. trades at a P/E of 4.8 (forward 2.5). TrendMatrix value score: 9.6/10. Verdict: Buy (Wait for Entry).
10 analysts cover IRWD with a consensus score of 3.9/5. Average price target: $6.
What does Ironwood Pharmaceuticals, Inc. do?Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies...
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.